Pushing the positive in p=0.05, RedHill says it’s ready for a pivotal IBD test
RedHill BioPharma $RDHL pushed hard to tout the data from a Phase II study for irritable bowel disease, but the stock started to slide this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
